Molecular genetics of astrocytomas and meningiomas

S. J. Dalrymple, Robert Brian Jenkins

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Although both spatial and temporal heterogeneity confound the description of the genetic events underlying glioma tumorigenesis, it is becoming evident that chromosome 17 loss and p53 inactivating mutations are probably involved early in the pathway of tumorigenesis of some, but not all, astrocytomas. Chromosome 10 loss and epidermal growth factor receptor amplification are seen predominantly in high-grade lesions, although they have not been shown to be independent prognostic indicators. Data is accumulating on the presence of a tumor suppressor gene on chromosome 9p, although the gene remains to be identified. The roles of chromosome 22 and the NF-2 tumor suppressor gene in the tumorigenesis of sporadic and familial meningiomas are discussed here, along with other nonrandom chromosomal alterations that are seen in both astrocytomas and meningiomas.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalCurrent Opinion in Neurology
Volume7
Issue number6
StatePublished - 1994

Fingerprint

Astrocytoma
Meningioma
Molecular Biology
Carcinogenesis
Tumor Suppressor Genes
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Epidermal Growth Factor Receptor
Glioma
Chromosomes
Mutation
Genes

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Molecular genetics of astrocytomas and meningiomas. / Dalrymple, S. J.; Jenkins, Robert Brian.

In: Current Opinion in Neurology, Vol. 7, No. 6, 1994, p. 477-483.

Research output: Contribution to journalArticle

@article{efd70b38511e4a819636345ded0ffe39,
title = "Molecular genetics of astrocytomas and meningiomas",
abstract = "Although both spatial and temporal heterogeneity confound the description of the genetic events underlying glioma tumorigenesis, it is becoming evident that chromosome 17 loss and p53 inactivating mutations are probably involved early in the pathway of tumorigenesis of some, but not all, astrocytomas. Chromosome 10 loss and epidermal growth factor receptor amplification are seen predominantly in high-grade lesions, although they have not been shown to be independent prognostic indicators. Data is accumulating on the presence of a tumor suppressor gene on chromosome 9p, although the gene remains to be identified. The roles of chromosome 22 and the NF-2 tumor suppressor gene in the tumorigenesis of sporadic and familial meningiomas are discussed here, along with other nonrandom chromosomal alterations that are seen in both astrocytomas and meningiomas.",
author = "Dalrymple, {S. J.} and Jenkins, {Robert Brian}",
year = "1994",
language = "English (US)",
volume = "7",
pages = "477--483",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Molecular genetics of astrocytomas and meningiomas

AU - Dalrymple, S. J.

AU - Jenkins, Robert Brian

PY - 1994

Y1 - 1994

N2 - Although both spatial and temporal heterogeneity confound the description of the genetic events underlying glioma tumorigenesis, it is becoming evident that chromosome 17 loss and p53 inactivating mutations are probably involved early in the pathway of tumorigenesis of some, but not all, astrocytomas. Chromosome 10 loss and epidermal growth factor receptor amplification are seen predominantly in high-grade lesions, although they have not been shown to be independent prognostic indicators. Data is accumulating on the presence of a tumor suppressor gene on chromosome 9p, although the gene remains to be identified. The roles of chromosome 22 and the NF-2 tumor suppressor gene in the tumorigenesis of sporadic and familial meningiomas are discussed here, along with other nonrandom chromosomal alterations that are seen in both astrocytomas and meningiomas.

AB - Although both spatial and temporal heterogeneity confound the description of the genetic events underlying glioma tumorigenesis, it is becoming evident that chromosome 17 loss and p53 inactivating mutations are probably involved early in the pathway of tumorigenesis of some, but not all, astrocytomas. Chromosome 10 loss and epidermal growth factor receptor amplification are seen predominantly in high-grade lesions, although they have not been shown to be independent prognostic indicators. Data is accumulating on the presence of a tumor suppressor gene on chromosome 9p, although the gene remains to be identified. The roles of chromosome 22 and the NF-2 tumor suppressor gene in the tumorigenesis of sporadic and familial meningiomas are discussed here, along with other nonrandom chromosomal alterations that are seen in both astrocytomas and meningiomas.

UR - http://www.scopus.com/inward/record.url?scp=0028019838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028019838&partnerID=8YFLogxK

M3 - Article

C2 - 7866578

AN - SCOPUS:0028019838

VL - 7

SP - 477

EP - 483

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 6

ER -